Aapro MS, Walko CM Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010; 21:(12)2316-2323

Arnold LM, McCarberg BH, Clair AG Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgrad Med. 2017; 129:(8)921-933

Ashley C, Dunleavey AOxford: Radcliffe Medical Press; 2019

: Association of Palliative Medicine of Great Britain and Ireland; 2012

Ben-Menachem E Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004; 45:13-18

Bockbrader HN, Radulovic LL, Posvar EL Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010; 50:(8)941-950

Bouhassira D Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris). 2019; 175:(1–2)16-25

Calkins A, Shurman J, Jaros M peripheral edema and weight gain in adult patients with painful diabetic peripheral neuropathy (dpn) receiving gabapentin enacarbil (gen) or pregabalin enrolled in a randomized phase 2 trial (I6-1.004). Neurology. 2014; 82

Chincholkar M Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018; 120:(6)1315-1334

Cerroni L Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37:(1)2-10

Dando TM, Perry CM Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004; 64:(7)777-794

Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1:(1)

Fujiwara Y, Toyoda M, Chayahara N Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. PLoS ONE. 2014; 9:(8)

He A, Alhariri JM, Sweren RJ, Kwatra MM, Kwatra SG Aprepitant for the treatment of chronic refractory pruritus. Biomed Res Int. 2017; 2017

Ho JM, Tricco AC, Perrier L, Chen M, Juurlink DN, Straus SE Risk of heart failure and edema associated with the use of pregabalin: a systematic review. Syst Rev. 2013; 2

Hosing C, Bassett R, Dabaja B Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015; 26:(12)2490-2495

Inoue T, Kimura M, Uchida J Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Int J Clin Oncol. 2017; 22:(3)600-604

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014; 70:(2)205.e1-222

Jeffry J, Kim S, Chen ZF Itch signaling in the nervous system. Physiology (Bethesda). 2011; 26:(4)286-292

Jiménez Gallo D, Albarrán Planelles C, Linares Barrios M, Fernández Anguita MJ, Márquez Enríquez J, Rodríguez Mateos ME Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant. Dermatologic Therapy. 2013; 27:(3)178-182

London: BMJ Publishing and the Royal Pharmaceutical Society; 2020

Joint Formulary Committee. 2021. (accessed 19 July 2022)

Jung JM, Chung CK, Kim CH, Yang SH, Choi Y Comparison of the use of opioids only and pregabalin add-on for the treatment of neuropathic pain in cervical myelopathy patients: a pilot trial. Sci Rep. 2020; 10:(1)

Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011; 147:(10)1153-1156

Kramer MS, Winokur A, Kelsey J Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004; 29:(2)385-392

Lee DW, Lee HJ, Kim HJ, Chang SH, Park DJ Two cases of pregabalin neurotoxicity in chronic kidney disease patients. NDT Plus. 2011; 4:(2)

Luckheeram RV, Zhou R, Verma AD, Xia B CD4+T cells: differentiation and functions. Clin Dev Immunol. 2012; 2012

Maguire A, Puelles J, Raboisson P, Chavda R, Gabriel S, Thornton S Early-stage Mycosis fungoides: epidemiology and prognosis. Acta Derm Venereol. 2020; 100:(1)

Maxwell SRJ, Coleman JJ, Bollington L, Taylor C, Webb DJ Prescribing Safety Assessment 2016: delivery of a national prescribing assessment to 7343 UK final-year medical students. Br J Clin Pharmacol. 2017; 83:(10)2249-2258

Nahidi Y, Meibodi NT, Ghazvini K, Esmaily H, Hesamifard M Evaluation of the association between epstein-barr virus and mycosis fungoides. Indian J Dermatol. 2015; 60:(3)

Naveed S, Faquih AE, Chaudhary AMD Pregabalin-associated Discontinuation Symptoms: A Case Report. Cureus. 2018; 10:(10)

Nursing and Midwifery Council. 2015. (accessed 19 July 2022)

OECD and European Union. 2013.

Palacios Zabalza I, López de Torre Querejazu A, Santos Ibañez A Papel del aprepitant en el manejo del prurito en un paciente con linfoma cutáneo de células T [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma]. Farm Hosp. 2014; 38:(2)145-147

Patel L, Lindley C Aprepitant–a novel NK1-receptor antagonist. Expert Opin Pharmacother. 2003; 4:(12)2279-2296

Prompila N, Eiamart W, Jumroen Y Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. Int J Clin Pharmacol Ther. 2017; 55:(10)811-817

Rodgers J, Bradley B, Kennedy PG Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Parasitol Int. 2007; 56:(4)321-324

Sanchez RI, Wang RW, Newton DJ Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004; 32:(11)1287-1292

Skopp G, Zimmer G Pregabalin–ein Arzneistoff mit Missbrauchspotential? [Pregabalin–a drug with abuse potential?]. Arch Kriminol. 2012; 229:(1–2)44-54

Stumpf A, Schneider G, Ständern S Psychosomatic and psychiatric disorders and psychologic factors in pruritus. Clinics in dermatology. 2018; 36:704-708

Tan T, Barry P, Reken S, Baker M Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010; 340

Tomita M, Koike H, Kawagashira Y Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013; 136:(Pt 8)2563-2578

van der Steen JT, Radbruch L, Hertogh CM White paper defining optimal palliative care in older people with dementia: a Delphi study and recommendations from the European Association for Palliative Care. Palliat Med. 2014; 28:(3)197-209

Verma V, Singh N, Singh Jaggi A Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12:(1)44-56

Vij A, Duvic M Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012; 51:(8)930-934

Weisshaar E, Szepietowski JC, Dalgard FJ European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019; 99:(5)469-506

Weisshaar E, Szepietowski JC, Darsow U European guideline on chronic pruritus. Acta Derm Venereol. 2012; 92:(5)563-581

Wilcox RA Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017; 92:(10)1085-1102

Willemze R Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37:(1)11-17

Willemze R, Cerroni L, Kempf W The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood. 2019 Sep 26;134(13):1112]. Blood. 2019; 133:(16)1703-1714

World Health Organization. 2002. (accessed 13 January 2021)

Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population [published correction appears in Pain Med. 2011 Aug;12(8):1294]. Pain Med. 2009; 10:(3)586-593

Zaccara G, Gangemi P, Perucca P, Specchio L The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011; 52:(4)826-836

Pharmacotherapeutics of aprepitant and pregabalin in neuropathic pain and refractory pruritus in a patient diagnosed with a cutaneous T-cell lymphoma

02 August 2022
Volume 4 · Issue 8



Palliative care nurse specialists are required to have a high level of knowledge and expertise in the management of complex symptoms. As a result of patient complexity, clinicians are often faced with advising on multiple drug regimes. This often requires clinical nurse specialists to have knowledge of pharmacotherapeutics to ensure safe and rational prescribing. In the form of a case study, the author has critically discussed the use of aprepitant and pregabalin in the management of neuropathic pain and refractory pruritus in a patient diagnosed with a cutaneous T cell lymphoma. These drugs are not routinely prescribed together and therefore the author has explored potential pharmacokinetic interactions.

Case presentation

The case presented a 49-year-old lady with an advanced metastatic cutaneous T-cell lymphoma with failed remission despite extensive oncological treatment. She was referrd to the to hospital specialist palliative care team for treatment of refractory pruritus and neuropathic pain.


Aprepitant is considered an effective anti-pruritic agent that is normally well tolerated; however, careful consideration must be taken because of extensive drug interactions. Caution is also required in patients with hepatic impairment. Pregabalin is often used in specialist palliative care for the management of neuropathic pain because of its efficacy and ease of titration. Caution must be taken in prescribing in patients with renal impairment. As pregabalin is not bound to plasma proteins nor metabolised by the liver, the risk of pharmacokinetic interaction with aprepitant is minimal. As both drugs cross the blood brain-barrier, clinicians must monitor for adverse central nervous system activity. This case study highlights the importance of pharmacotherapeutics in ensuring safe and rational prescribing, with the need to continue to integrate this knowledge into future practice as nurse prescribers.

The author is employed as a clinical nurse specialist in a hospital specialist palliative care team. Palliative care is an ‘approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness’ (World Health Organization, 2002). It is the role of the specialist palliative care team to provide expert advice on the management of complex symptoms while providing holistic and supportive care to patients and their families (Association of Palliative Medicine, 2012). This requires a unique approach to clinical assessment, as nurses must not only manage physical symptoms but also provide psychosocial, spiritual, emotional and practical support.

Because of an ageing population, people are living longer with multiple comorbidities (OECD and European Union, 2013) and this often presents challenges for specialist palliative care because of the increasing patient complexities. Clinical nurse specialists are required to have a high level of knowledge and skill when providing advice on complex symptom management (van de Steen et al, 2014). This also includes knowledge of pharmacotherapeutics to ensure safe and rational prescribing of medications (Maxwell et al, 2017). Pharmacotherapeutics describes the clinical indication for giving a drug and the effect it has on the body.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month